INTRODUCTION
Depression is a com mon psychi atric problem in th e e lde rly, a lt ho ugh th e exac t pr eva len ce is u ncertain. Th e Nation a l Institute of M ental H ealth (NIM H) Epidemiologica l C atchm ent Ar ea (ECA) progr am round a pr eval en ce rat e or 2.5% fo r all affec tive di sorders in peopl e aged 65 yea rs a nd olde r ( I) . Howeve r, depression ca n be diffi cult to recogn ize a nd may manifest diITerently in olde r ad u lts . T hus, t he ECA rat e ' Jo hns Hopki ns U nivers ity, Dep art men ts of Psychi a try & Mental Hygiene, Ba lt imore, Marylan d 2U niversity of Oklah om a , Dep a rtm ent of Psychi at ry, Tu lsa , O kla homa This work was fund ed in pa rt by th e Na t ional Institute of Ment al Healt h training gra nt 5T 32MH I4592 34 ma y be an underestimate (2) . Blaz er (3) an alyz ed th e ECA dat a a nd found th a t d epressi ve sym ptoms were report ed in 27% of those ag ed 60 yea rs or olde r. This high pr eval en ce of depressive sym ptoms in th e elde rl y, togethe r with t his segme n t of th e population increasin g fast er th an a ny ot he r, indi cat es th e need for an tid epressa nt th e rapy th at is highl y effec tive, well tolerat ed , a nd rela tively fr ee of side e ffec ts and dru g interacti on s.
Bupropion (BUP) , on e of th e " second ge ne ra tion" a ntid e pressa n ts, was originally introduced in 1985. Th e uni cyclic aminok eton e is a uniqu e a n tide pr essan t in structure, (4) is well tolerat ed , a nd has few side e ffec ts (5) or dru g int eract ions (6) ; th ese cha ra cte ristics su ite it particul arly well lor use both in th e elde rly a nd in th e med ica lly ill. In March 1986, however, bupropi on imm ed ia te release (IR) was withdrawn from th e market aft e r reports indi cat ed a n increased rat e of se izures in bulimic patients (7) . In May 1989, bupropion IR was re-int rodu ced with a redu ced maximum do sage recommendation int ended to decreas e th e incid en ce of seizu res. In lat e 1996, th e Food and Drug Administration (FDA) approved a sus ta ined-release (SR ) form of bupropion , whi ch is rep orted to furth er reduce conce rns abou t se izures. However, toxic effects in add iti on to se izure s have been no ted wit h bupropi on, including th e exace rba tion or ini ti ation of psych oti c sym ptom s.
PHARMACOLOGY
Bupropion weakly blocks dopamin e upt ak e (8) . This is not beli eved to ade q ua te ly acco un t for it s antid epressant activity, however, a nd a norad ren ergic mecha nism has a lso bee n sugges ted (8) . Oral ad m inist ra tion of bupropion result s in ra pid a bsorpt ion, a nd bupropion undergoes exte nsive fir st pass met ab ol is m (9) . Th e met aboli sm of bupropi on results in th e formation of three maj or m et ab oli tes: hyd roxybu pro pion (HB) , threoh ydrobupropion (TB) , and e ryt h rohyd ro bupro pion (E B) (9) . Lei zu re ( 10) found th e half lives of BUP, TB , EB, a nd HB to be 9.8, 19.8, 26.8 , a nd 22.2 hou rs, resp ectively. In 1995, how ever, Sweet ( 11) found th e half lives for BUP , TB , EB, a nd HB to be increased in th e elde rly a t 32.4, 38.8, 6 1.4, a nd 34.2 hou rs, respectively. Furtherm ore, th e elde rly accumulat e a n inordinat e a mo u nt of bupropion met ab olit es ( I I) . Met ab oli sm of bupropi on SR results in th e sa me break down product s as does m et abolism of th e IR form. Future st udy, however, will be necessary to lea rn mo re a bou t th e ph arm acokin etic properti es of bupropi on SR a nd how th ese com pa re to I he IR form . Excr etion of'bupropion occurs throu gh th e urin e (87 %) a nd feces ( 10%), with onl y 0.5% excre ted un ch an ged (9) . Decr eases in liver fun cti on , an d pr esumab ly kidn ey fun cti on , impair e lim ina tion, result in incr eased blood levels of bupro pion a nd it s m et ab olites, a nd incr eas e th e cha nce of toxicity ( 12) .
EFFICACY
Kane, (13) in a study of 38 d epressed pati ents 55 yea rs or old e r, foun d no differen ce in effi cacy between th ose randomly designat ed to recei ve eit he r a mean bupropion dose of 323 mgld a y (high dose) or a mea n of 150 mg/ day (low dose).
Lik ewise, Branconnier, (14) in a st udy of 63 depressed pa ti ents 55 years or olde r, found no significa nt differen ces in efficacy bet ween th ose ran domly designated to receive bupropion a t eit he r 450 rug/ day (high dose) or 150 rng/day (low dose). However, h igh do se bupropion d em on strated fast er onse t of action and gr eat er a nxiolyt ic acti vit y th an low dose bupropi on . Pr esk orn ( 15) found a curvilinea r relation ship between a ntide pressa nt efficacy a nd bupropion t rou gh plasma conce n t ration , with efficacy d ecr ea sed with eit he r ve ry high or very low t rou gh plasma level s. Lik ewise, Go lden ( 16) found poor efficacy to be associa ted wit h high bupropion met ab olite conce n t ra tions . Bupropion is not th e only a nti de pressa nt in which reduced do ses in th e elde rly have been recommend ed. For exa m ple, J arvic ( 17) found that do ses as low as 25 mg and 50 mg/day of imipramin e a rc effec tive in treating older ad ults with depression .J a rvie ( 17) a lso not ed t hat furth er dosage increases were not likely to be success ful but were likely to produ ce und esirable side effec ts .
SIDE EFFECTS
Ov era ll, bupropion is well to lerat ed and exh ibits few sid e effects (5). For exa m ple, Feighner (5) found no differen ce in treatm ent-em ergent adv erse eve n ts between bupropion a nd Iluox et in c, on e of th e se lec tive seroto nin rcuptakc inhibitors (SSIUs). Agit ation a nd excite me nt a re th e most co m mon sid e effec ts associat ed with th e di scontinuation of bupropi on ( 18) . Althou gh Prien ( 19) has suggest ed th at bup ropi on may be associa te d with a nti de p ressa nt induced man ia less oft en than with ot he r a n tide pressa n ts, ra re report s of bupropi on ind uced ma nia do ex ist. For exam ple, Bittm an (20) rep ort s th e case of a 78 year old man ta king lith ium who became grand iose a nd manic when bupropi on was sta rted. Bupro pion demons trat es lilli e to no a nt icho line rg ic, a ntihistim in ic, or a ntiad re ne rg ic effect (2 1). Th e re is no known ca rd iotox icity a nd it does not ca use or t hos ta tic hypot en sion (22) . In fact, bupropion has been found to be a useful age nt in treating pa ti ents wit h heart d isease (23, 24) . On ave rage, bupropion ca uses only mild weight loss a nd mi ni mall y a ffects appetite (25) . Bupropion is th e on ly a ntide p ressan t report ed to improve sex ua l fu nction (26 ) . Few drug int eractions hav e been not ed with bupropion , a nd inhib iti on of cytochrom e P450 live r isocnzym es has not been rep orted (6). Thus, not only is bupropi on free of man y of t he side effec ts of t he older tri cyclic a ntide pressa nts, but a lso it has th e followin g advantages over t he newer se lec tive se ro tonin rc-upta ke in hibitors: fewe r sexual sid e effec ts, fewe r d rug in te ractions, and an absence of live r e nzyme inhibiti on.
BUPROPIO N AND SEIZU RES
In 1989, David son , (27) in a review of over four th ou sand cases, co nclud ed that th e incid en ce of se izu res associa ted with bupropi on th e rap y is a ppro ximate ly 0.4 %; thi s was deem ed to be e it he r no different fr om or j us t slig ht ly h igh e r than th e incid en ce of se izu res with th e use of ot he r tri cyclic a nd tetracyclic a nti dep ressants. In 1993, a prosp ective st udy with ove r three th ou sand pati e n ts re produced this sa me 0.4 % se izu re incid en ce rat e with buprop ion th e rapy (28) . Davidson (27) found that seve ral pati en t cha rac te ristics we re associat ed with an incr eased risk of se izure wit h bupropi on usage: pri or history of se izures, hist ory of orga nic brain di sease, hist ory of a n ea ting disord er, doses gre a te r t ha n 45 0 mg/day, rap id dose esca la tion, a nd hig h plasm a levels of bupropi on or it s metabolites. T o m inim ize th e risk of se izures, t he 1998 Ph ysicians Desk Refe ren ce (29) (PDR) recommen ds a n initi al bu pr op ion IR dose of 100 mg twice a day for a mi nimum of t hree days before incr easing th e dose to 100 mg three ti mes a day. If in a few wee ks respon se is not ade q ua te th e dose can be rai sed to a maximum 01' 450 mg/day (29) .
Peak bupropi on plasm a levels are 50% lowe r with th e SR formulation t ha n wit h th e IR form (6) . The risk of seizu res with bupropi on th erapy is cor re la te d with th e peak plasm a level. Th erefor e it is not surpris ing th at t he incid e nce of se izu res wit h th e SR formulation , with doses not exceed ing 300 mg/d ay, is lowe r (0 . 1%) t han t ha t found with th e IR form (0.4%) (30) . Th e efficacy a nd side effec t profil e of th e two forms of bupropion arc ot he rwise sim ila r (6) . Th e PDR recom mends begin ning bupropion SR treatm ent a t 150 rug/day as a sing le do se (29) . Th is ca n be increased to 150 mg twice a day, th e reco mm end ed ta rget dose, as ea rly as day four (29) . A maximum dose of 200 mg twice a d ay is recommend ed (29) . Howeve r, give n high plasm a bupropi on levels and accu m u la tion of b upro pion met ab olit es in th e elde rly, eve n th e target dose of 300 mg/d ay of bupropi on SR m ay be excess ive when t reat ing geria tric depression.
BUPR OPIO N Al'IJD PSYCH O SIS
A review of th e lit e ratu re u ncove red seve n cases of bupropion treat m ent e me rge n t psych osis or d eliriu m wit h psych oti c featu res (3 1-37) . Golden (3 1) reported th at fou r out of 13 bupro pion t reat ed pati e nt s develop ed psych otic symp toms, on ly one of who had no hist ory of psych osis. In two of t he cases, psychot ic symptoms a ppe a re d to be dose-relat ed. Likewi se, Goo d e (32) reported t hat three out of n ine patien ts di agn osed with schizoaffe ctive di sorder expe rie nce d exace rba tions of psychot ic sym pto ms wh en treat ed with bupropi on . Beck er (33) rep ort ed t ha t two ou t of twel ve pati ents, both of who had a previou s d iagn osis of sch izoph re nia, expe rie nce d a be r ra n t beli efs and visua l expe rie nce s with bupropi on treatm ent. Va n-Putt e n (34) report ed a case of ac u te d elirium with psychotic featu res in a pati ent tr eated wit h bupropion. Am es (35) report ed three cas es of bupropion induced psych osis, wit h e me rge nt sym ptoms including d elu sion s as well as audit ory a nd visua l hallu cin ati ons. A hi story of psychotic sym p toms was present in two of th e three indi vid ua ls. Bupropion my pr ecipitat e psych osis by blocking dopamin e upt ak e a nd ca using dopaminergic overdrive (36) . Lib erzon (36) rep ort ed a case of bupropi on t rea t me nt e me rge nt delirium with psych oti c features in a pati ent who had a hist ory of psych osis a nd was taking th e dopamine ago nist a manta d ine. Go etz (37) rep orted th e onse t or worsening of hallucination s or con fusion wit h buprop ion t reatm e nt in th ree pati ents with Parkinson s di sease who were rec eiving a dop a mine ago nis t, eit he r amant adin e or levodopa . Fr om thi s review, bup ropi on induced psych osis a ppears to be more likel y to occu r in patients wit h ce rta in risk factors. Vulne rab le pa ti e nt s includ e th ose tak ing dopamin ergic m edi cations or th ose with a history of psych osis (3 1-37) .Johnston (38) recomm ends that , in patients with a history of psychosis, bupropi on not be used as first lin e t rea t me n t.
Thes e reports contrast with th e less than 4% rat e of treatm e nt emerge nt psychotic symptoms reported in a total of2,398 patients who received bup ro pion up to 1985 (38) . Thus, th e incid en ce of treatment e me rge nt psych osis with bu pro pion, wh en individual pa ti ent cha rac te ristics are di sr egarded , a ppears to be no gre a ter th an th at see n with ot he r antidepressant s (38) . However, th e pr ecedi ng da ta su ggest th at bupropion is ca pa ble of inducing or exace rba ting psych oti c sym ptom s, particularly in th e pr esen ce of ce r ta in vulnerabilities.
DISC USSIO N Th e elde rly m ay be more vu lnerable to bupropion indu ced psychosis and ot he r tox ic effec ts than youn ger ad ult s with d epression. A possibl e mech anism for increased risk of bupropion tox icity in th e elde rly is th at th ey have high peak plasm a bupropion levels a nd acc u mu la te bupropion m etabolites ( I I) . The elde rly a re a lso more like ly th an younge r ad ults to hav e impairments of liver or kidn ey fu nct ion, bot h ofwhich are expected to result in eleva ted bupropi on and bupropi on me ta bolite leve ls ( 12) . U ntowa rd drug int eracti ons a re an ot he r possibl e expla na t ion for bu pro pion indu ced toxic effec ts, a lt ho ug h drug int eracti ons have been rep orted ra rely wit h bupropion (39) . Onset or wor sening or psych osis a nd co nfus ion has been associat ed with co ncom ita n t ad m inist ra tion or bupropion with th e dopamine ago n ists levodopa (37) and amant adin e (36) , findings whi ch suppor t the dopamin ergic ove rd rive hypothesis. Lithium (35) and sel ective seroton in reuptake inhibitors (34) have likewise bee n associat ed with th e onse t or worsening of d elirium or psych osis wh en com bine d with bupropion.
In concl usion, bupropion possesses man y cha racte ris tics th at off er adva ntages ove r ot he r a n tide pressa nts in th e t reatm ent or dep ression both in t he elde rly a nd in th e m edi call y ill; th ese includ e excelle n t tole rability, few side effec ts (5) , and an a bse nce or P450 liver e nzyme inhibition or dru g int eracti on s (6) . H oweve r, pot ential toxi c effects, particularly seizu res a nd psychosis, may result from high buprop ion plasma level s and from th e accumulation of bupropi on m et ab olit es in t he elde rly or in those with impaired renal or live r fun ction ( 12) . Pat ients receiving dop aminergic m ed ications are also at incr eased risk of developing psychotic sym pto ms wh en given bupropion (36, 37) . Thus, low dos es (75-225 m g/day) of bupropion a re re commend ed in th e elde rly, th os e with liver or renal dysfuncti on , a nd in th ose a lr ea dy ta king dopamine agonists. In add ition, bupropion sho u ld eit he r be avo ided or used with ex t re me ca ution in a nyo ne wh o is a t incr eased risk or seizures or wh o has a hist ory or psych osis or an eating di sorde r. Also, bupropion s ho uld not be com bine d with other m edi cation s known to lower th e sei zure thresh old . Future wor k es ta blish ing a th erapeutic plasm a level range Ior bupropion in th e elde rly would facilita te th e sa fe a nd effec t ive use or thi s uniqu e a ntide pressan t.
